AIM: To estimate the hospitalisation costs borne by the New Zealand Government for the influenza pandemic in 2009 (with uncertainty). METHODS: Data were derived from national and local New Zealand studies, and from a combined Australia and New Zealand study on intensive care unit (ICU) use and costs. Probabilistic sensitivity analysis was performed (2000 iterations). RESULTS: We estimated the total mean cost to the hospital sector in New Zealand of NZ$30.5 million (95% uncertainty interval (UI): 22.3 to 39.5 million) [US$14.8 to 26.3 million]. The mean cost per capita was NZ$7.01. In an additional cost-effectiveness analysis (using a hypothetical counterfactual relating to no hospital care), the results were suggestive that hospital care was likely to be a relatively cost-effective means of preventing death from pandemic influenza. CONCLUSIONS: These high hospitalisation costs for a relatively non-severe pandemic indicate the potential value of preventive measures (e.g., vaccination) and of investing in pandemic planning and other control measures to reduce person-to-person spread.
AIM: To estimate the hospitalisation costs borne by the New Zealand Government for the influenza pandemic in 2009 (with uncertainty). METHODS: Data were derived from national and local New Zealand studies, and from a combined Australia and New Zealand study on intensive care unit (ICU) use and costs. Probabilistic sensitivity analysis was performed (2000 iterations). RESULTS: We estimated the total mean cost to the hospital sector in New Zealand of NZ$30.5 million (95% uncertainty interval (UI): 22.3 to 39.5 million) [US$14.8 to 26.3 million]. The mean cost per capita was NZ$7.01. In an additional cost-effectiveness analysis (using a hypothetical counterfactual relating to no hospital care), the results were suggestive that hospital care was likely to be a relatively cost-effective means of preventing death from pandemic influenza. CONCLUSIONS: These high hospitalisation costs for a relatively non-severe pandemic indicate the potential value of preventive measures (e.g., vaccination) and of investing in pandemic planning and other control measures to reduce person-to-person spread.
Authors: Mazhar Hussain; Henry D Galvin; Tatt Y Haw; Ashley N Nutsford; Matloob Husain Journal: Infect Drug Resist Date: 2017-04-20 Impact factor: 4.003
Authors: Constantine Vardavas; Katerina Nikitara; Konstantinos Zisis; Konstantinos Athanasakis; Revati Phalkey; Jo Leonardi-Bee; Helen Johnson; Svetla Tsolova; Massimo Ciotti; Jonathan E Suk Journal: BMJ Open Date: 2021-04-29 Impact factor: 2.692